This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, Z. Articles by Lüscher, T. F. Search for Related Content PubMed PubMed Citation Articles by Yang, Z. Articles by Lüscher, T. F.

(Circulation. 1997;95:1870-1876.)
© 1997 American Heart Association, Inc.

Articles

Different Effects of Thrombin Receptor Activation on Endothelium and Smooth Muscle Cells of Human Coronary Bypass Vessels

Implications for Venous Bypass Graft Failure

Presented in part at the 67th Annual Scientific Sessions of the American Heart Association, Dallas, Tex, November 14-17, 1994.

Zhihong Yang, MD; Frank Ruschitzka, MD; Ton J. Rabelink, MD; Georg Noll, MD; Friedgard Julmy; Hana Joch; Verena Gafner; Ivan Aleksic, MD; Ulrich Althaus, MD; Thomas F. Lüscher, MD

From the Departments of Cardiology, Cardiovascular Research (Z.Y., F.R., G.N., F.J., H.J., V.G., T.F.L.), and Cardiovascular and Thoracic Surgery (U.A.), University Hospital, Inselspital Bern, Switzerland; the Department of Nephrology and Hypertension (T.J.R.), University Hospital Utrecht, Netherlands; and the Department of Heart and Thoracic Surgery (I.A.), University Hospital, Göttingen, Germany.

Correspondence to Thomas F. Lüscher, MD, Professor of Medicine, Cardiology, Cardiovascular Research, University Hospital, Rämistrasse 100, CH-8091, Zürich, Switzerland.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background Thrombin is implicated in coronary bypass graft disease; it cleaves its receptor's extracellular N-terminal domain and unmasks a new N-terminus as a tethered ligand. We studied the effects of thrombin receptor activation in human internal mammary artery (IMA) and saphenous vein (SV).

Methods and Results To study the effects of thrombin receptor activation on vasomotion, isolated blood vessels were suspended for isometric tension recording, and the effects on cell proliferation were studied in cultured smooth muscle cells (SMCs) of IMA and SV. Thrombin receptor expression in IMA and SV was analyzed by reverse transcription polymerase chain reaction and immunohistology. Receptor function was studied by analyzing the activation of mitogen-activated protein kinase (p42^MAPK). In IMA thrombin evoked endothelium-dependent relaxations (65±5%) that were mimicked by thrombin receptor agonist peptide (TRAP) and reduced by the thrombin inhibitors recombinant (r-) hirudin and D-Phe-Pro-Arg-chloromethyl ketone (PPACK) (P<.05). In SV thrombin caused contractions (36±5% of 100 mmol/L KCl) that were inhibited by r-hirudin or PPACK (P<.05) but not mimicked by TRAP. In SMCs thrombin induced more pronounced [³H]thymidine incorporation (inhibited by r-hirudin or PPACK) in SV than IMA (P<.05), but activation of p42^MAPK was similar in both vessels. TRAP induced weaker activation of p42^MAPK than thrombin and did not stimulate [³H]thymidine incorporation in SMCs of SV or IMA. Immunohistology and RT-PCR demonstrated that the endothelium and SMCs of IMA and SV express thrombin receptor.

Conclusions Functional thrombin receptors are present on endothelium and SMCs of IMA and SV. Endothelial thrombin receptors mediate relaxation in IMA but not SV. Thrombin causes much more pronounced contraction and proliferation in SMCs of SV than IMA independent of tethered receptors, suggesting other thrombin receptors exist. These differences of thrombin receptor activation in IMA and SV may be important in the development of and therapy for graft disease.

Key Words: arteries • veins • receptors • grafting

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Previous studies have demonstrated the lower patency rate of SV bypass grafts compared with IMA grafts.¹ This may be due to different endothelial production of vasodilators (ie, NO and prostacyclin) and platelet–vessel wall interactions^{2 3} as well as different contractile and proliferative properties of SMCs.^{4 5} Thrombin is an important modulator of all these events,⁶ and antithrombotic therapy improves patency and clinical events in patients receiving venous grafts.⁷

Thrombin affects a wide range of cell types, such as platelets, monocytes, ECs, and SMCs,^{2 8 9 10 11} and hence is an important regulator of platelet–vessel wall interaction.¹² Indeed, thrombin stimulates platelets to release large amounts of vasoconstrictors (ie, thromboxane A₂ and serotonin^{12 13} ), which in turn causes profound vasoconstriction and platelet aggregation. On the other hand, thrombin activates the ECs of certain blood vessels to release NO and prostacyclin, both of which antagonize vascular contraction and inhibit platelet aggregation.^{12 14} Thrombin also stimulates SMC contraction and proliferation in animals^{11 15 16} and is believed to play an important role in vasospasm and neointimal formation.^{17 18}

A human thrombin receptor has been cloned¹⁹ that is a member of the seven-transmembrane domain receptor family coupled to guanine nucleotide–binding protein (G protein).¹⁹ Thrombin activates its receptor by an unprecedented mechanism in which the serine protease cleaves the receptor's N-terminal extracellular domain, generating a new N-terminus that then functions as a tethered peptide ligand and activates the receptor.¹⁹ A homologous synthetic peptide (SFLLRNPNDKYEPF) corresponding to the tethered ligand sequence of the human thrombin receptor (ie, TRAP) can mimic specific receptor activation under some, but not all, conditions.^{11 19 20 21 22} Signal transduction studies have demonstrated that thrombin receptor stimulation induces an array of intracellular events,^{23 24} such as activation of MAPKs ^{24 25 26} and a pathway activated by growth factor tyrosine kinase receptors such as platelet-derived growth factor receptor.²⁷ This signaling mechanism has been proposed as one of the major pathways for transmitting extracellular stimuli to the cell nucleus regulating cell proliferation²⁷ and is essential for the growth of CCL39 cells.²⁸

The thrombin receptor is expressed in ECs and vascular SMCs as well as platelets.^{15 19} In experimental animals it is upregulated in SMCs immediately after vascular injury and throughout neointimal development,²⁹ a process that occurs during and after venous bypass implantation.^{2 30 31} We investigated different effects of thrombin receptor activation on endothelium (ie, endothelium-dependent modulation of vascular tone) and SMC function (contraction and proliferation) of human IMA and SV. Such differences might be of great biological and clinical interest as they may contribute to the different functions and patencies of arterial and venous bypass grafts.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Chemicals and Materials
Acetylcholine hydrochloride, bradykinin, L-norepinephrine bitartrate, thrombin, TRAP, and r-hirudin (activity, 6000 U/mg; 1 U neutralizes 1 U=3x10^-8 mol/L of thrombin) were from Sigma. PPACK was from Calbiochem. All materials for cell culture were from GIBCO BRL. The concentrations of the drugs are expressed as final concentrations in the organ-chamber solution or in cell-culture medium. All drugs were dissolved in distilled water for organ-chamber or in PBS for cell-culture experiments except PPACK, which was dissolved in 50 mmol/L sodium acetate and 1% BSA (pH 4.5) at a stock solution of 10^-2 mol/L and diluted further in PBS.

Assessment of Vasomotion
IMAs and SVs were obtained intraoperatively.^{2 3 4} After the vessels were removed, they were placed in modified Krebs-Ringer bicarbonate solution at 4°C (in mmol/L): NaCl 118, KCl 4.7, CaCl₂ 2.5, MgSO₄ 1.2, KH₂PO₄ 1.2, NaHCO₃ 25.0, edetate calcium disodium 0.026, and glucose 11.1. The blood vessels were dissected free, cut into 5-mm-long rings, and suspended in organ chambers filled with the solution described above at 37°C (95% O₂/5% CO₂); changes in isometric tension were recorded with force transducers (Statham Universal UC2).

Prior to the experiment, the rings were stretched and repeatedly exposed to norepinephrine (3x10^-7 mol/L for arteries and 10^-7 mol/L for veins) until the optimal length-tension relationship was reached^{4 32} ; they were then allowed to equilibrate for 45 minutes. The endothelium was removed from some rings by gentle rubbing of the intraluminal surface with a cotton swab. The presence or absence of the endothelium was confirmed by the presence or absence of a relaxation to acetylcholine (10^-6 mol/L; IMA) or bradykinin (10^-6 mol/L; SV).^{4 32}

To study endothelium-dependent responses to thrombin and TRAP, experiments were performed in parallel rings with or without endothelium of arteries or veins contracted with norepinephrine (3x10^-7 or 10^-7 mol/L, respectively). Thrombin (3x10^-8 mol/L), TRAP (10^-5 mol/L), thrombin treated with r-hirudin (5 U/mL; activity, 6000 U/mg; 1 U neutralizes 1 U=3x10^-8 mol/L of thrombin), or PPACK (10^-6 mol/L) for 15 minutes at 37°C were added on top of that contraction. This concentration of thrombin exerts maximal effects.¹² Because of the frequent development of tachyphylaxis to thrombin, concentration-response curves were avoided. To study the direct contractile effects of thrombin and TRAP on SMCs, the agents were added to the quiescent rings with or without endothelium of both arteries and veins.

Cultivation of ECs and SMCs
ECs were isolated from HUVECs, SVs, and IMAs.³³ Briefly, fresh blood vessels were harvested in cold, sterile RPMI 1640 medium with 100 U/mL penicillin and 100 µg/mL streptomycin. The vessels, cleaned of connective tissue and adventitia, were incubated with collagenase type II (75 U/mL) for 15 minutes in PBS. Cell pellets were then collected by centrifugation at 1000 rpm for 10 minutes, seeded in culture dishes coated with 25 µg/mL human fibronectin, and cultured in RPMI 1640 supplemented with 20 mmol/L L-glutamine, HEPES buffer solution, 100 U/mL penicillin, 100 µg/mL streptomycin, 50 µg/mL EC growth supplement, 25 µg/mL heparin, and 20% FCS. The next day cells were washed with the medium to eliminate blood cell contamination. ECs were identified by their typical cobblestone and nonoverlapping appearance as well as by indirect immunofluorescence staining using specific antibodies against von Willebrand factor. Cells from the third passage were used.

Vascular SMCs were cultivated from SVs and IMAs obtained from patients undergoing coronary bypass surgery using an explant technique.^{5 34} Briefly, the cells were cultured in DMEM containing 20% FCS supplemented with 20 mmol/L L-glutamine and 10 mmol/L HEPES buffer solution, 100 U/mL penicillin, and 100 µg/mL streptomycin in a humidified atmosphere (95% air/5% CO₂) at 37°C. Culture medium was replaced every 3 days. Cells were passaged by cell dissociation solution. Experiments were performed on passages 3 through 6. SMCs were characterized by their typical morphological pattern (multilayer sheets and "hills and valleys") and by indirect immunofluorescence staining using specific mouse monoclonal antibodies against human SMC -actin (Sigma).^{5 34}

DNA Synthesis
SMCs in DMEM containing 20% FCS were seeded on 12-well plates (density, 2x10⁴/mL) for 24 hours to allow attachment. Culture media were then replaced with serum-free DMEM containing all ingredients described above except for 0.2% BSA instead of FCS. Cells in serum-free DMEM medium were incubated for 48 hours to achieve quiescence; the cells were then stimulated with thrombin (1.5x10^-8 to 1.5x10^-7 mol/L), TRAP (10^-7 to 10^-5 mol/L), thrombin treated with r-hirudin (0.5 to 5 U/mL), or PPACK (10^-6 to 10^-5 mol/L) as described above. [³H]thymidine incorporation was assayed after 24 hours of stimulation.^{5 34} Incorporated radioactivity was measured by using a ß-counter (ICN, Intertechnique).

MAPK Activation
p42^MAPK activation (phosphorylation) by thrombin or TRAP was analyzed by mobility shifts on Western blots. Quiescent SMCs that had rested in serum-free medium for 48 hours were stimulated with thrombin (3x10^-8 mol/L) or TRAP (10^-5 mol/L) at different times as indicated in "Results." After being stimulated, the cells were washed immediately with ice-cold PBS and harvested with cold extraction buffer (120 mmol/L sodium chloride, 50 mmol/L Tris, 20 mmol/L sodium fluoride, 1 mmol/L benzamidine, 1 mmol/L dithiothreitol, 1 mmol/L EDTA, 6 mmol/L EGTA, 15 mmol/L sodium pyrophosphate, 0.8 µg/mL leupeptin, 30 mmol/L p-nitrophenyl phosphate, 0.1 mmol/L phenylmethylsulfonyl fluoride, and 1% Nonidet P40). The cell debris was removed by centrifugation at 12 000g for 10 minutes at 4°C. The samples (20 µg) were treated with 5x Laemmli's SDS-PAGE sample buffer (0.35 mol/L Tris-Cl, pH 6.8, 15% SDS, 56.5% glycerol, and 0.0075% bromophenol blue), heated at 95°C for 3 minutes, and subjected to a 10% SDS-PAGE gel for electrophoresis. The proteins were then transferred to Immobilon-P filter papers (Millipore AG) by using a semidry transfer unit (Hoefer Scientific Instruments). The membranes were blocked by using 5% skim milk in PBS-Tween buffer (0.1% Tween 20; pH=7.5) for 1 hour and incubated with anti-p42^MAPK antibodies (1:3000 for MK12 [GIBCO BRL] or 1:1000 for C14 [Santa Cruz Biotech]). The immunoreactive bands were detected by using an enhanced chemiluminescence system (Amersham).

Thrombin Receptor Analyses
RT-PCR
Total RNA was isolated from cultured SMCs and ECs of IMA and SV and HUVECs (as positive control) by using TRIzol reagent (GIBCO BRL) according to the manufacturer's instructions. cDNA was produced from these RNA samples by RT [Superscrip (R)-reverse transcriptase] of 4 µg total RNA from each sample. The cDNA encoding the thrombin receptor was amplified by using PCR with the two primers 5'-TGTGAACTGATCATGTTTATG-3' and 5'-TTCGTAAGATAAGAGATATGT-3'¹⁹ (MWG Biotech). PCR was then performed for 30 cycles (denaturing at 97°C for 15 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 60 seconds). Specific amplification of thrombin receptor cDNA with these primers should yield a 708-bp product.¹⁹ Control PCR was performed without RT or with templates from the same RNA isolation with the primers 5'-CAGGAATTCGGTGAAGGTCGGAGTCAACGG-3' and 5'-AGTGGATCCGGTCATGAGTCCTTCCACGAT-3' (MWG Biotech) for the housekeeping gene GAPDH (20 cycles). Specific amplification of GAPDH with these primers yielded a 517-bp product as expected. PCR products were then separated by 1% agarose gel electrophoresis and visualized using the Visionary (R) gel documentation system (Bio Cell Consulting).

Immunohistology
IMAs and SVs were harvested, dissected free, frozen immediately in liquid nitrogen after removal, and kept at -70°C until used. Serial 6-µm frozen sections of IMAs and SVs were cut in a cryostat (-20°C) and mounted on clean glass slides. After air drying, the slides were fixed in paraformaldehyde according to routine procedures. To block nonspecific binding the slides were soaked in TBS and then incubated in 4% human albumin (Behringwerke AG) solution in TBS for 30 minutes at room temperature. Sections were then incubated for 60 minutes at room temperature with or without a polyclonal rabbit thrombin receptor antibody (kindly provided by Dr H. Theunissen, Department of Biotechnology and Biochemistry, Organon, Netherlands) raised against TRAP, the new N-terminus peptide sequence of thrombin receptor (1:10). The sections were then washed three times for 15 minutes with TBS-Tween (0.05% Tween 20) followed by incubation with biotinylated goat anti-rabbit secondary antibody (Vector Laboratories) for 1 hour at room temperature. After washing with TBS-Tween as described above, the slides were incubated with avidin-biotin–horseradish peroxidase complex. After washing with TBS-Tween as above, bound peroxidase was detected by incubation with the chromogenic substrate 3,3' diaminobenzidine (Sigma; 50 mg in 100 mL of 0.1 mol/L PBS, to which was added 33 µL H₂O₂, pH=7.35). After 10 minutes, the slides were rinsed in deionized water, dehydrated, and mounted.

Statistics
Data are given as mean±SEM. Contractions are expressed as percent of the increase in tension to 100 mmol/L KCl. Relaxations are expressed as percent decrease in tension of the contraction to norepinephrine. Stimulated [³H]thymidine incorporation is expressed as percent increase above control. In all experiments, n equals the number of patients from whom blood vessels were obtained. Student's t test for paired observations and ANOVA followed by Scheffé's test for repeated measurements were used for statistical analysis. A two-tailed probability value <.05 was considered significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Thrombin and Endothelium-Dependent Relaxations
In IMAs with endothelium contracted with norepinephrine (3x10^-7 mol/L), thrombin (3x10^-8 mol/L) induced a potent endothelium-dependent relaxation (65±5%, n=6; Fig 1). In contrast, in the SVs, even in the presence of the endothelium, thrombin evoked a small contraction (13±20%, n=6, P<.05 versus artery; Fig 1).

View larger version (19K): [in this window] [in a new window]   Figure 1. Bar graph shows responses of isolated IMAs and SVs to thrombin (3x10-8 mol/L). Vessels were contracted with norepinephrine (3x10-7 and 10-7 mol/L) before thrombin was added. In IMA thrombin caused profound relaxation; in SV small contractions occurred (P<.05).

In IMAs with endothelium contracted with norepinephrine (3x10^-7 mol/L), TRAP (10^-5 mol/L) induced endothelium-dependent relaxations (53±6%, n=4; Fig 2) that were comparable to thrombin-induced relaxations (3x10^-8 mol/L, NS). The relaxations to thrombin (43±6%, n=12) were markedly reduced by the thrombin inhibitors r-hirudin (5 U/mL; 12±3%, n=5) and PPACK (10^-6 mol/L; 7±2%, n=5, P<.05 versus thrombin).

View larger version (39K): [in this window] [in a new window]   Figure 2. Bar graph shows endothelium-dependent relaxations to thrombin and TRAP in isolated human IMAs. In arteries contracted with norepinephrine (3x10-7 mol/L) thrombin caused marked relaxations that were inhibited by r-hirudin (5 U/mL) or PPACK (10-6 mol/L) (*P<.05). The endothelium-dependent relaxations caused by TRAP (10-5 mol/L) were similar to those of thrombin (NS).

Thrombin and Vascular Contractions
In quiescent IMAs with or without endothelium, thrombin (3x10^-8 mol/L) had no effects on vascular tone (n=8). In contrast, in quiescent SVs with ECs, thrombin (3x10^-8 mol/L) induced a pronounced contraction (36±5% of 100 mmol/L KCl, n=11) that was markedly inhibited by 5 U/mL r-hirudin (4.5±1%, n=9, P<.05 versus control) and 10^-6 mol/L PPACK (1±0.6%, n=8, P<.05 versus control) (Fig 3). The contractile effects of thrombin in the vein were not affected by removal of the endothelium (data not shown; n=18).

View larger version (20K): [in this window] [in a new window]   Figure 3. Bar graph shows contractile responses to thrombin and TRAP in quiescent SVs. Thrombin caused marked contractions in the vein that were inhibited by r-hirudin (5 U/mL) or PPACK (10-6 mol/L). Contractions to TRAP (10-5 mol/L) were markedly less than those to thrombin. *P<.05.

The contractions induced by thrombin in quiescent SVs could only be partially mimicked by TRAP. Indeed, TRAP at a high concentration (10^-5 mol/L) induced only a small contraction compared with thrombin (5.9±1%, n=6, P<.05 versus thrombin) (Fig 3).

Thrombin and MAPK Activation
In cultured SVs as well as IMA SMCs, thrombin (3x10^-8 mol/L) stimulated p42^MAPK phosphorylation in a time-dependent manner as demonstrated by the slower mobility of the phosphorylated form on Western blots. The activation of p42^MAPK started at 2 minutes and reached the maximum at 5 to 10 minutes; dephosphorylation then caused a return to the basal level at 20 minutes (Fig 4). Interestingly, TRAP at the highest concentration (10^-5 mol/L) was unable to stimulate [³H]thymidine incorporation in these cells (see below), but like thrombin, it stimulated p42^MAPK phosphorylation, although with lesser potency (Fig 4).

View larger version (23K): [in this window] [in a new window]   Figure 4. Activation of p42MAPK by thrombin and TRAP in human SMCs. In both SV (top) and IMA (bottom) SMCs thrombin stimulated p42MAPK activation time dependently as demonstrated by mobility shift on Western blot. The activation of p42MAPK by thrombin was not fully matched by TRAP.

Thrombin and Cell Proliferation
In cultured SV SMCs, thrombin (1.5x10^-8 to 1.5x10^-7 mol/L) concentration dependently stimulated [³H]thymidine incorporation (maximum=242±38%, n=4, P<.05), which was much more pronounced than that in the IMA (maximum=151±39, n=4, P<.05) (Fig 5A). In contrast to thrombin, TRAP (10^-7 to 10^-5 mol/L) had no effects on cell proliferation in either arteries or veins (n=5). The stimulation of [³H]thymidine incorporation by thrombin (3x10^-7 mol/L) in SV SMCs was markedly inhibited by 0.5 to 5 U/mL r-hirudin (160±17%, n=6, P<.05 versus thrombin) and 10^-6 to 10^-5 mol/L PPACK (118±11, n=6, P<.01 versus thrombin) (Fig 5B).

View larger version (30K): [in this window] [in a new window]   Figure 5. Graphs show proliferative responses to thrombin and TRAP in human SV and IMA SMCs. A, Thrombin caused a more pronounced [3H]thymidine incorporation in SVs than IMAs, while TRAP had no effects in either SVs or IMAs. B, Stimulation of [3H]thymidine incorporation by thrombin (solid bar) in SVs was inhibited by r-hirudin (; 5 U/mL) or PPACK (; 10-6 to 10-5 mol/L). Open bar indicates control. *P<.05 vs control, **P<.05 vs thrombin alone.

Thrombin Receptor Expression
As demonstrated by RT-PCR, ECs and SMCs from both SV and IMA as well as HUVECs expressed the thrombin receptor (Fig 6). In addition, immunohistological studies with a specific polyclonal antibody against the thrombin receptor in intact IMAs (Fig 7A) and SVs (Fig 7C) showed the presence of thrombin receptor protein expression in endothelium as well as SMCs of both the arteries and veins (brown staining).

View larger version (38K): [in this window] [in a new window]   Figure 6. RT-PCR demonstrating thrombin receptor gene expression in human SVs and IMAs. Thrombin receptor transcript (Th-R) of the expected size of 708 bp with the desired two primers described in "Methods" was detected by RT-PCR in cultured HUVECs and ECs from SV (SVEC) and IMA (IMAEC) as well as in SMCs of IMA (IMASMC) and SV (SVSMC).

View larger version (60K): [in this window] [in a new window]   Figure 7. Immunohistochemistry demonstrating thrombin receptor protein expression in intact IMAs (A and B) and SVs (C and D). A, Thrombin receptor protein is demonstrated in endothelium and SMCs of IMA (brown staining; magnification x200); B, negative control for IMA; C, thrombin receptor protein is shown in endothelium and SMCs of SV (brown staining; magnification x100); D, negative control for SV. L indicates lumen; M, media.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
This study demonstrates different biological effects of thrombin and thrombin receptor activation on endothelium and smooth muscle of human IMAs and SVs. Although the endothelium and smooth muscle of both arteries and veins expressed the tethered thrombin receptor, activation of the receptor on the endothelium caused endothelium-dependent relaxations (due to release of NO and prostacyclin¹² ) in the arteries but not veins. Furthermore, thrombin induced contractions in intact veins but not arteries and induced a much more pronounced proliferation (in cultured SMCs) in the former than the latter. This response in SV SMCs was not mimicked by TRAP, indicating that a mechanism(s) independent of the tethered receptor might exist in venous SMCs that would mediate contraction and proliferation.

Although discovered as a central enzyme in the coagulation cascade, thrombin affects a variety of functions in platelets, monocytes, endothelium, and vascular SMCs. It is likely that not all effects of thrombin occur via the same mechanism. Indeed, in the coagulation cascade, thrombin acts as an enzyme, generating fibrin from fibrinogen.⁶ These enzymatic effects are crucial for the stabilization of evolving platelet clots. Recently, a tethered thrombin receptor has been cloned.¹⁹ During activation, thrombin cleaves the receptor's N-terminal extracellular domain, generating a new N-terminus that activates the receptor as a tethered ligand. TRAP is a specific tool to activate this tethered receptor. Hence, the results of this study demonstrate that in the IMA thrombin causes endothelium-dependent relaxations that are related to the formation of NO and prostacyclin¹² via activation of the tethered thrombin receptor. Indeed, in IMAs the relaxation to thrombin and TRAP were of identical potency. The fact that r-hirudin and PPACK, which bind to and inhibit thrombin's catalytic epitope, markedly reduced endothelium-dependent relaxations further supports this hypothesis. Finally, RT-PCR and immunohistology demonstrated receptor mRNA and protein in endothelium of IMAs.

In contrast, SVs did not exhibit endothelium-dependent relaxations to thrombin but exhibited contractions. This is not due to the absence of the tethered thrombin receptor, since its presence could be demonstrated in venous endothelium by RT-PCR and immunohistology. Thus, the thrombin receptor in the SV endothelium-although expressed-is not linked to NO synthase or cyclooxygenase.

In quiescent SVs, thrombin caused marked contractions that were similar in preparations with or without endothelium, confirming that thrombin directly contracted SV SMCs. Interestingly, TRAP (at a high concentration that fully mimicked the effects of thrombin in IMAs) caused negligible contractions in SVs. Hence, although the tethered thrombin receptor is expressed in SV SMCs (again confirmed by RT-PCR and immunohistology), contractions to thrombin are not mediated by this receptor. Indeed, in other cells not all responses of thrombin can be explained by activation of the tethered thrombin receptor.^{11 21 22 24} A second thrombin receptor has been demonstrated in tethered thrombin–receptor gene knockout mice.³⁵ Interestingly, neither thrombin nor TRAP could induce contractions in IMA SMCs even in preparations without endothelium, although these cells express the tethered receptor. Hence, the tethered receptor may exert other unknown functions in IMA SMCs.

Furthermore, we found that thrombin is a more potent stimulus of SMC proliferation of SV than IMA. In venous SMCs, thrombin activated intracellular growth-signaling pathways such as p42^MAPK, one of the major mechanisms leading to cell proliferation,^{27 28} and stimulated DNA synthesis. In contrast, TRAP had no mitogenic effects under these conditions and induced weaker activation of p42^MAPK than thrombin. Thus, thrombin stimulates SV SMC proliferation via a mechanism(s) other than activation of the tethered receptor. Alternatively, activation of additional pathway(s), one involving the tethered thrombin receptor and one involving other receptor(s), might be required to exert proliferation. The proliferative as well as contractile effects were inhibited by the thrombin inhibitors r-hirudin and PPACK, which inhibit the catalytic domain of the enzyme. This inhibition suggests that a second receptor that also possesses proteolytic activity³⁵ might be involved.

Similar to the thrombin stimulation of SV SMCs, in IMA SMCs thrombin and TRAP stimulated p42^MAPK, demonstrating that thrombin and thrombin receptor activation in arterial SMCs have a functional role in stimulating intracellular signal transduction pathways; however, this leads to much weaker cell proliferation in the artery than the vein. This must be due to the different growth properties of SMCs from IMAs and SVs.⁵ It is possible that a growth-inhibitory mechanism is dominant in IMA SMCs, which may explain IMA resistance to atherosclerosis as a native vessel and as a graft.^{1 36}

The different responses to thrombin of the IMA and SV may be of importance for their performance as coronary bypass grafts. The observation that SMCs might express more than one thrombin receptor may have important therapeutic implications. Development of a new class of selective thrombin receptor antagonists may have great therapeutic potential.

	Selected Abbreviations and Acronyms

 

EC = endothelial cell HUVEC = human umbilical vein endothelial cell IMA = internal mammary artery MAPK = mitogen-activated protein kinase NO = nitric oxide PCR = polymerase chain reaction PPACK = D-Phe-Pro-Arg-chloromethyl ketone r-hirudin = recombinant hirudin RT = reverse transcription SMC = smooth muscle cell SV = saphenous vein TBS = Tris-buffered saline TRAP = thrombin receptor agonist peptide

	Acknowledgments

 
This study was supported by the Swiss National Research Foundation (grant No. 32-32541.91/2); the Swiss Cardiology Foundation, Bern; and the Wilhelm Bitter Foundation, Basel, Switzerland. Ton J. Rabelink was sponsored by the Royal Dutch Academy of Sciences.

Received September 4, 1996; revision received November 20, 1996; accepted November 25, 1996.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LAR, Gill CC, Taylor PC, Sheldon WC, Proudfit WL. Influence of the internal mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med. 1986;314:1-6. [Abstract]

2. Lüscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, Von Segesser L, Yang Z, Turina M, Grädel G, Weber E, Bühler FR. Difference between endothelium-dependent relaxations in arterial and in venous coronary bypass grafts. N Engl J Med. 1988;319:462-467. [Abstract]

3. Yang Z, Stulz P, Von Segesser L, Bauer E, Turina M, Lüscher TF. Different interactions of platelets with arterial and venous coronary bypass vessels. Lancet. 1991;337:939-943. [Medline] [Order article via Infotrieve]

4. Yang Z, Diederich D, Schneider K, Siebenmann R, Stulz P, Von Segesser L, Turina M, Bühler FR, Lüscher TF. Endothelium-derived relaxing factor and protection against contractions induced by histamine and serotonin in the human internal mammary artery and in the saphenous vein. Circulation. 1989;80:1041-1048. [Abstract/Free Full Text]

5. Predel H-G, Yang Z, Von Segesser L, Turina M, Bühler FR, Lüscher TF. Implications of pulsatile stretch on growth of saphenous vein and mammary artery smooth muscle. Lancet. 1992;340:878-879. [Medline] [Order article via Infotrieve]

6. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 1994;90:1522-1536. [Abstract/Free Full Text]

7. Israel DH, Adams PC, Chesebro JH, Fuster V. Antithrombotic therapy in the coronary vein graft patient. Clin Cardiol. 1991;14:283-295. [Medline] [Order article via Infotrieve]

8. Berndt MC, Phillips DR. Platelet membrane proteins: composition and receptor function. In: Gordon JL, ed. Platelets in Biology and Pathology. Amsterdam, Netherlands: Elsevier/North Holland; 1981:43-74.

9. Bar-Shavit R, Kahn A, Wilner GD, Fenton JW II. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science. 1983;220:728-731. [Abstract/Free Full Text]

10. De Mey JG, Vanhoutte PM. Endothelium-dependent inhibitory effects of acetylcholine, adenosine, thrombin, and arachidonic acid in the canine femoral artery. J Pharmacol Exp Ther. 1982;222:166-173. [Abstract/Free Full Text]

11. Tesfamariam B. Distinct receptors and signaling pathways in -thrombin- and thrombin receptor peptide-induced vascular contractions. Circ Res. 1994;74:930-936. [Abstract/Free Full Text]

12. Yang Z, Arnet U, Bauer E, Von Segesser L, Siebenmann R, Turina M, Lüscher TF. Thrombin-induced endothelium-dependent inhibition and direct activation of platelet–vessel wall interaction: role of prostacyclin, nitric oxide, and thromboxane A₂. Circulation. 1994;89:2266-2272. [Abstract/Free Full Text]

13. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 1989;80:199-205.

14. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057-1068. [Medline] [Order article via Infotrieve]

15. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW II, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993;91:94-98.

16. Huang CL, Ives HE. Growth inhibition by protein kinase C late in mitogenesis. Nature. 1987;329:849-850. [Medline] [Order article via Infotrieve]

17. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17(suppl B):77B-88B.

18. Wilcox JN. Thrombin and other potential mechanisms underlying restenosis. Circulation. 1991;84:432-435. [Free Full Text]

19. Vu TKH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068. [Medline] [Order article via Infotrieve]

20. Hung DT, Vu TKH, Nelken NA, Coughlin SR. Thrombin-induced events in non-platelet cells are mediated by the unique proteolytic mechanism established for the cloned platelet thrombin receptor. J Cell Biol. 1992;116:827-832. [Abstract/Free Full Text]

21. Kramer RM, Roberts EF, Hyslop PA, Utterback BG, Hui KY, Jakubowski JA. Differential activation of cytosolic phospholipase A₂ (cPLA₂) by thrombin and thrombin receptor agonist peptide in human platelets: evidence for activation of cPLA₂ independent of the mitogen-activated protein kinases ERK1/2. J Biol Chem. 1995;270:14816-14823. [Abstract/Free Full Text]

22. Shankar R, De la Motte CA, Poptic EJ, DiCorleto PE. Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. J Biol Chem. 1994;269:13936-13941. [Abstract/Free Full Text]

23. Berk BC, Taubman MB, Griendling KK, Cragoe EJ, Fenton JW, Brock TA. Thrombin-stimulated events in cultured vascular smooth muscle cells. Biochem J. 1991;274:799-805.

24. van Obberghen-Schilling E, Pouysségur J. -Thrombin receptors and growth signaling. Semin Thromb Hemost. 1993;19:378-385. [Medline] [Order article via Infotrieve]

25. Gardner AM, Vaillancourt RR, Johnson GL. Activation of mitogen-activated protein kinase/extracellular signal-regulated kinase by G protein and tyrosine kinase oncoproteins. J Biol Chem. 1993;268:17896-17901. [Abstract/Free Full Text]

26. Meloche S, Seuwen KK, Pagés G, Pouysségur J. Biphasic and synergistic activation of p44^MAPK (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol Endocrinol. 1992;6:845-854. [Abstract/Free Full Text]

27. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci U S A. 1993;90:5889-5892. [Abstract/Free Full Text]

28. Pagés G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouysségur J. Mitogen-activated protein kinases p42^MAPK and p44^MAPK are required for fibroblast proliferation. Proc Natl Acad Sci U S A. 1993;90:8319-8323. [Abstract/Free Full Text]

29. Wilcox JN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong C, Hayzer DJ, Horaist C, Hanson SR, Lumsden L, Salam TA, Kelly AB, Harker LA, Runge M. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res. 1994;75:1029-1038. [Abstract/Free Full Text]

30. Kern WH, Dermer GB, Lindesmith GG. The intimal proliferation in aortocoronary saphenous vein grafts: light and electron microscopic studies. Am Heart J. 1972;84:771-777. [Medline] [Order article via Infotrieve]

31. Smith SH, Geer JC. Morphology of saphenous vein coronary bypass grafts: 7 to 116 months after surgery. Arch Pathol Lab Med. 1983;107:13-18. [Medline] [Order article via Infotrieve]

32. Yang Z, Von Segesser L, Bauer E, Stulz P, Turina M, Lüscher TF. Different activation of endothelial L-arginine and cyclooxygenase pathway in human internal mammary artery and saphenous vein. Circ Res. 1991;68:52-60. [Abstract/Free Full Text]

33. Jaffe E, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.

34. Yang Z, Noll G, Lüscher TF. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation. 1993;88:832-836. [Abstract/Free Full Text]

35. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature. 1996;381:516-519. [Medline] [Order article via Infotrieve]

36. Singh RN. Atherosclerosis and internal mammary arteries. Cardiovasc Intervent Radiol. 1983;6:72-77.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				S.K. Payeli, R. Latini, C. Gebhard, A. Patrignani, U. Wagner, T.F. Luscher, and F.C. Tanner Prothrombotic Gene Expression Profile in Vascular Smooth Muscle Cells of Human Saphenous Vein, but Not Internal Mammary Artery Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 705 - 710. [Abstract] [Full Text] [PDF]

				B. Gigante, A. Bellis, R. Visconti, M. Marino, C. Morisco, V. Trimarco, G. Galasso, F. Piscione, N. De Luca, J. A. Prince, et al. Retrospective Analysis of Coagulation Factor II Receptor (F2R) Sequence Variation and Coronary Heart Disease in Hypertensive Patients Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1213 - 1219. [Abstract] [Full Text] [PDF]

				M. Gaudino, N. Luciani, F. Glieca, C. Cellini, C. Pragliola, C. Trani, F. Burzotta, G. Schiavoni, A. Anselmi, and G. Possati Patients with in-stent restenosis have an increased risk of mid-term venous graft failure. Ann. Thorac. Surg., September 1, 2006; 82(3): 802 - 804. [Abstract] [Full Text] [PDF]

				V. de Waard, E. K. Arkenbout, M. Vos, A. I.M. Mocking, H. W.M. Niessen, W. Stooker, B. A.J.M. de Mol, P. H.A. Quax, E. N.T.P. Bakker, E. VanBavel, et al. TR3 Nuclear Orphan Receptor Prevents Cyclic Stretch-Induced Proliferation of Venous Smooth Muscle Cells Am. J. Pathol., June 1, 2006; 168(6): 2027 - 2035. [Abstract] [Full Text] [PDF]

				C. Barandier, J.-P. Montani, and Z. Yang Mature adipocytes and perivascular adipose tissue stimulate vascular smooth muscle cell proliferation: effects of aging and obesity Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1807 - H1813. [Abstract] [Full Text] [PDF]

				N. Tabuchi, M. Shichiri, A. Shibamiya, T. Koyama, F. Nakazawa, J. Chung, S. Hirosawa, and M. Sunamori Non-viral in vivo thrombomodulin gene transfer prevents early loss of thromboresistance of grafted veins Eur. J. Cardiothorac. Surg., November 1, 2004; 26(5): 995 - 1001. [Abstract] [Full Text] [PDF]

				D. Chilov, C. Fux, H. Joch, and M. Fussenegger Identification of a novel proliferation-inducing determinant using lentiviral expression cloning Nucleic Acids Res., September 15, 2003; 31(18): e113 - e113. [Abstract] [Full Text] [PDF]

				R. Bobe, X. Yin, M.-C. Roussanne, O. Stepien, E. Polidano, C. Faverdin, and P. Marche Evidence for ERK1/2 activation by thrombin that is independent of EGFR transactivation Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H745 - H754. [Abstract] [Full Text] [PDF]

				J. J. Bosnjak, K. Terata, H. Miura, A. Sato, A. C. Nicolosi, M. McDonald, S. A. Manthei, T. Saito, O. A. Hatoum, and D. D. Gutterman Mechanism of thrombin-induced vasodilation in human coronary arterioles Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1080 - H1086. [Abstract] [Full Text] [PDF]

				K. Pajusola, M. Gruchala, H. Joch, T. F. Luscher, S. Yla-Herttuala, and H. Bueler Cell-Type-Specific Characteristics Modulate the Transduction Efficiency of Adeno-Associated Virus Type 2 and Restrain Infection of Endothelial Cells J. Virol., October 11, 2002; 76(22): 11530 - 11540. [Abstract] [Full Text] [PDF]

				A. Y. Kim, P. L. Walinsky, F. D. Kolodgie, C. Bian, J. L. Sperry, C. B. Deming, E. A. Peck, J. G. Shake, G. B. Ang, R. H. Sohn, et al. Early Loss of Thrombomodulin Expression Impairs Vein Graft Thromboresistance: Implications for Vein Graft Failure Circ. Res., February 8, 2002; 90(2): 205 - 212. [Abstract] [Full Text] [PDF]

				J. E. Freedman Thrombin, Thrombomodulin, and Extracellular Signal-Regulated Kinases Regulating Cellular Proliferation Circ. Res., April 13, 2001; 88(7): 651 - 653. [Full Text] [PDF]

				Z. Yang, T. Kozai, B. van de Loo, H. Viswambharan, M. Lachat, M. I. Turina, T. Malinski, and T. F. Luscher HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1691 - 1697. [Abstract] [Full Text] [PDF]

				F. T. Ruschitzka, R. H. Wenger, T. Stallmach, T. Quaschning, C. de Wit, K. Wagner, R. Labugger, M. Kelm, G. Noll, T. Rulicke, et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin PNAS, October 10, 2000; 97(21): 11609 - 11613. [Abstract] [Full Text] [PDF]

				F. Ruschitzka, U. Moehrlen, T. Quaschning, M. Lachat, G. Noll, S. Shaw, Z. Yang, D. Teupser, T. Subkowski, M. I. Turina, et al. Tissue Endothelin-Converting Enzyme Activity Correlates With Cardiovascular Risk Factors in Coronary Artery Disease Circulation, September 5, 2000; 102(10): 1086 - 1092. [Abstract] [Full Text] [PDF]

				L. Gruberg, G. Dangas, R. Mehran, M. K. Hong, R. Waksman, G. S. Mintz, K. M. Kent, A. D. Pichard, L. F. Satler, A. J. Lansky, et al. Percutaneous revascularization of the internal mammary artery graft: short- and long-term outcomes J. Am. Coll. Cardiol., March 15, 2000; 35(4): 944 - 948. [Abstract] [Full Text] [PDF]

				C. I. Chardigny, K. Van der Perre, S. Simonet, J.-J. Descombes, J.-N. Fabiani, and T. J. Verbeuren Platelets and prostacyclin in arterial bypasses: implications for coronary artery surgery Ann. Thorac. Surg., February 1, 2000; 69(2): 513 - 519. [Abstract] [Full Text] [PDF]

				R. D. Rosenberg and W. C. Aird Vascular-Bed-Specific Hemostasis and Hypercoagulable States N. Engl. J. Med., May 20, 1999; 340(20): 1555 - 1564. [Full Text] [PDF]

				J. G. Motwani and E. J. Topol Aortocoronary Saphenous Vein Graft Disease : Pathogenesis, Predisposition, and Prevention Circulation, March 10, 1998; 97(9): 916 - 931. [Abstract] [Full Text] [PDF]

				Z. Yang, B. S. Oemar, T. Carrel, B. Kipfer, F. Julmy, and T. F. Luscher Different Proliferative Properties of Smooth Muscle Cells of Human Arterial and Venous Bypass Vessels : Role of PDGF Receptors, Mitogen-Activated Protein Kinase, and Cyclin-Dependent Kinase Inhibitors Circulation, January 20, 1998; 97(2): 181 - 187. [Abstract] [Full Text] [PDF]

				A. Y. Kim, P. L. Walinsky, F. D. Kolodgie, C. Bian, J. L. Sperry, C. B. Deming, E. A. Peck, J. G. Shake, G. B. Ang, R. H. Sohn, et al. Early Loss of Thrombomodulin Expression Impairs Vein Graft Thromboresistance: Implications for Vein Graft Failure Circ. Res., February 8, 2002; 90(2): 205 - 212. [Abstract] [Full Text] [PDF]

				M. Eto, C. Barandier, L. Rathgeb, T. Kozai, H. Joch, Z. Yang, and T. F. Luscher Thrombin Suppresses Endothelial Nitric Oxide Synthase and Upregulates Endothelin-Converting Enzyme-1 Expression by Distinct Pathways: Role of Rho/ROCK and Mitogen-Activated Protein Kinase Circ. Res., September 28, 2001; 89(7): 583 - 590. [Abstract] [Full Text] [PDF]

This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, Z. Articles by Lüscher, T. F. Search for Related Content PubMed PubMed Citation Articles by Yang, Z. Articles by Lüscher, T. F.